ChipDX Develops New Prognostic Breast Cancer Test for Research Purposes | GenomeWeb

When Ryan Van Laar created his molecular diagnostics and personalized medicine research company, ChipDX, two years ago, he aimed to provide clinicians with a cheaper and easier way to identify the best treatment solutions for cancer patients. "I had the idea [for ChipDX] thinking about the existing model of clinical diagnostics, where a clinician orders a test and then sends the specimen to a remote laboratory where a genetic profile is generated and then one small set of genes is used to generate a result," Van Laar says.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.